Analyst: ConMed ripe for M&A spree May 19, 2015 by Fink Densford ConMed, in the middle of an under-appreciated turnaround, could be poised to augment its growth via selective acquisitions, according to Leerink Partners analyst Richard Newitter. Newitter, who upgraded CNMD shares to “outperform” and boosted the price target to $64 from $60, wrote in […]
Perella Weinberg Partners
Feds charge ex-JP Morgan exec, father in medtech insider trading scheme
Federal prosecutors in New York this week charged a father-and-son team with insider trading connected with a spate of mergers in the medical device arena.
